The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
Open accessAbstract
Abstract Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magro, C., Mulvey, J. J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., Baxter-Stoltzfus, A., & Laurence, J. (2020) · Translational Research · doi:10.1016/j.trsl.2020.04.007 · Cited by 2,183
Acute respiratory distress syndrome
Thompson, B. T., Chambers, R. C., & Liu, K. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608077 · Cited by 1,807
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 655
Complement as a target in COVID-19?
Risitano, A. M., Mastellos, D. C., Huber-Lang, M., Yancopoulou, D., Garlanda, C., Ciceri, F., & Lambris, J. D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0320-7 · Cited by 484
Self-citationCiceri, F., Beretta, L., Scandroglio, A. M., Colombo, S., Landoni, G., Ruggeri, A., Peccatori, J., D’Angelo, A., De Cobelli, F., Rovere-Querini, P., et al. (2020) · Critical Care and Resuscitation · doi:10.51893/2020.2.pov2 · Cited by 483
Self-citationGao, T., Zhu, L., Liu, H., Zhang, X., Wang, T., Fu, Y., Li, H., Dong, Q., Hu, Y., Zhang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01133-5 · Cited by 436
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Self-citationWill Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?
Campbell, C. M., & Kahwash, R. (2020) · Circulation · doi:10.1161/circulationaha.120.047419 · Cited by 267
Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention
Mastellos, D. C., Yancopoulou, D., Kokkinos, P., Huber‐Lang, M., Hajishengallis, G., Biglarnia, A. R., Lupu, F., Nilsson, B., Risitano, A. M., Ricklin, D., et al. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12419 · Cited by 206
Self-citationJiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0063-8 · Cited by 195
Complement-Dependent Mechanisms and Interventions in Periodontal Disease
Hajishengallis, G., Kajikawa, T., Hajishengallis, E., Maekawa, T., Reis, E. S., Mastellos, D. C., Yancopoulou, D., Hastürk, H., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00406 · Cited by 95
Self-citationApplying complement therapeutics to rare diseases
Reis, E. S., Mastellos, D. C., Yancopoulou, D., Risitano, A. M., Ricklin, D., & Lambris, J. D. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.08.009 · Cited by 58
Self-citationProtective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock
van Griensven, M., Ricklin, D., Denk, S., Halbgebauer, R., Braun, C., Schultze, A., Hönes, F., Koutsogiannaki, S., Primikyri, A., Reis, E. S., et al. (2018) · Shock · doi:10.1097/shk.0000000000001127 · Cited by 48
Self-citationSafety profile after prolonged C3 inhibition
Reis, E. S., Berger, N., Wang, X., Koutsogiannaki, S., Doot, R. K., Gumas, J. T., Foukas, P. G., Resuello, R. R. G., Tuplano, J. V., Kukis, D. L., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.09.004 · Cited by 45
Self-citationComplement inhibition decreases early fibrogenic events in the lung of septic baboons
Silasi‐Mansat, R., Zhu, H., Georgescu, C., Popescu, N. I., Keshari, R. S., Peer, G. T., Lupu, C., Taylor, F. B., Pereira, H. A., Kinasewitz, G. T., et al. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12667 · Cited by 39
Self-citationBerger, N., Alayi, T. D., Resuello, R. R. G., Tuplano, J. V., Reis, E. S., & Lambris, J. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00560 · Cited by 34
Self-citationLindorfer, M. A., Cook, E. M., Reis, E. S., Ricklin, D., Risitano, A. M., Lambris, J. D., & Taylor, R. P. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.08.017 · Cited by 24
Self-citationTaming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?
Mastellos, D. C., Reis, E. S., Biglarnia, A., Waldman, M. A., Quigg, R. J., Huber-Lang, M. S., Seelen, M. A., Daha, M. R., & Lambris, J. D. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.11.010 · Cited by 17
Self-citation
Cited by
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
COVID-19 Image Data Collection: Prospective Predictions are the Future
Cohen, J. P., Morrison, P., Dao, L., Roth, K., Duong, T., & Ghassem, M. (2020) · Machine Learning for Biomedical Imaging · doi:10.59275/j.melba.2020-48g7 · Cited by 927
Skendros, P., Mitsios, A., Chrysanthopoulou, A., Mastellos, D. C., Metallidis, S., Rafailidis, P., Ntinopoulou, M., Sertaridou, E., Tsironidou, V., Tsigalou, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141374 · Cited by 786
Self-citationImmunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
“cently, the compstatin-based complement C3 inhibitor AMY-101 was administered to a patient with ARDS due to COVID-19, in which very good clinical responses with a high level of safety were reported [116].”
Metadata
- Authors
- Mastaglio, S., Ruggeri, A., Risitano, A. M., Angelillo, P., Yancopoulou, D., Mastellos, D. C., Huber-Lang, M., Piemontese, S., Assanelli, A., Garlanda, C., Lambris, J. D., & Ciceri, F.
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 215
- Pages
- 108450
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W3022757001
- Cited by
- 283
- References
- 18
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.